Posttraumatic Stress Disorder
Conditions
Brief summary
The aim of this study is to asses the effects of the NMDA receptor full agonist D-serine while used as adjuvant treatment for individuals suffering from chronic posttraumatic stress disorder (PTSD). Dysfunction of neurotransmission mediated at NMDA receptor plays a cardinal role in the pathophysiology of PTSD and PTSD patients typically suffer from cognitive dysfunctions and avoidance& depressive symptomatology that may be mediated by NMDA receptor function deficits. Thus, enhancement of NMDA activity by using D-serine may be beneficial in the treatment of PTSD. The study design involves two 6 week periods during which the participants will be randomly assigned to receive treatment with D-serine (\ 2g /dy)and placebo. This design allows each participant the opportunity to respond to the experimental treatment.
Interventions
DRUGD-serine (~2g /day)
Two 6 weeks treatment arms under a cross over design. In one arm adjuvant treatment with experimental medication (D-serine \ 2g /day), in the second arm adjuvant treatment with placebo (\ 2g /day)
Sponsors
Herzog Hospital
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
25 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
• Chronic PTSD (DSM-IV diagnosis)
Exclusion criteria
* Other psychiatric diagnosis * Substance abuse * Unstable medical condition
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| CAPS scores | 6 week treatment |
Countries
Israel
Outcome results
None listed